The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Regeneration

BPC-157 Oral (Tablet)

The healing peptide BPC-157 as a tablet, especially obvious for the gastrointestinal tract, where it originally comes from.

1 min read 9 sources

To the product To the sources
White tablet bottle with a black TPD label for BPC-157 Oral on a white podium, next to it a long chain of blue and white glass spheres as a molecule model in a bright lab
Compound in phase 1 · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

Length
15 amino acids

Pentadecapeptide from a gastric juice protein, stable in human gastric juice according to a review2

Studies preclinical
35 of 36

systematic review in orthopaedic sports medicine, only one human study5

All published human studies
30 people

three small studies with dosing into the knee, the bladder or a vein, none by mouth6

First completed study by mouth
40 people

gummies with BPC-157 over 8 weeks, no comparison group, results not published8

Half-life (rat, dog)
<30 minutes

after dosing into a vein or muscle, then broken down into small fragments and amino acids4

  • BPC-157 is a peptide of 15 amino acids derived from a protein in gastric juice. The tablet contains the same compound as the capsule and the vial.21
  • According to a review by the developer group, BPC-157 is stable in human gastric juice. In rat studies it also worked via the drinking water, for example in healing intestinal fistulas.23
  • Almost all data come from animal and cell studies: 35 of 36 studies in a systematic review were preclinical.5
  • All published human studies combined cover 30 people, none of them with a tablet. A tablet study (phase 1, 2015) and a gummy study (40 people, completed 2025) are on the registry, neither has results.678
  • On the registry BPC-157 has not gone beyond phase 1. BPC-157 is not approved. Everything here is the state of research, not a recommendation.79
Profile

Updated May 2026

Class
Pentadecapeptide

healing, oral

Use
Oral

tablet, 500mcg

Focus
Gastrointestinal tract
WADA
Banned

peptides

Sizes
500 mcg

1 size in the shop

Contents 13 sections
  1. At a glance
  2. What is BPC-157 Oral?
  3. How it works
  4. How to take it
  5. Dosing
  6. What the research shows
  7. Research status
  8. Side effects
  9. Storage
  10. Related compounds
  11. FAQ
  12. Glossary
  13. Sources

What is BPC-157 Oral?

BPC-157 Oral is the tablet form of the well-known healing peptide BPC-157 (see lexicon entry). Since BPC-157 originally comes from gastric juice and is closely tied to gastrointestinal healing, oral use is especially obvious for the digestive tract.

Comparison

Same compound, different form

BPC-157 as injection, tablet, capsule and in the oral blend, as stated in the TPD lexicon. Tap a card to open its entry.

Injection BPC-157 BPC-157 TB-500 1 of 2 compounds
Tablet BPC-157 Oral (Tablet) BPC-157 TB-500 1 of 2 compounds
Capsule BPC-157 Oral (Capsule) BPC-157 TB-500 1 of 2 compounds Tablet with TB-500 BPC + TB Oral Blend BPC-157 TB-500 2 of 2 compounds

Simplified: tablet and capsule are the same in principle. In humans only injection, bladder instillation or infusion has been published so far. 6

How it works

BPC-157 is associated with the repair of connective tissue and especially the gastrointestinal mucosa and acts on healing signaling routes. With oral intake the effect is likely strongest locally in the digestive tract, systemic absorption is limited.

The mechanism in detail is in the BPC-157 entry.

Where it acts

Where BPC-157 acted in experiments

Tap a point or a card. All sites from animal studies, there is no confirmed receptor.

  1. Stomach and oesophagus

    Mucosal protection against alcohol and painkiller damage, sphincters strengthened (rats)2

    Observed in trials
  2. Gut

    Colon-skin fistulas also healed with BPC-157 in the drinking water (rats)3

    Observed in trials
  3. Skin and wounds

    Faster healing of incision, burn and diabetic wounds (rats)1

    Observed in trials
  4. Tendons and ligaments

    Better healing of tendons, ligaments and muscle in animal models5

    Observed in trials
  5. Liver and kidney

    Broken down into fragments, excreted via urine and bile (rats, dogs)4

    Observed in trials
Stomach and intestine of translucent glass with soft folds, small groups of blue molecules lying on the inner wall
Taken orally, most plausibly local in the digestive tract. Symbolic image.

How to take it

Oral, usually one tablet (500mcg) per day with some water. For gastrointestinal topics often on an empty stomach.

Closed white tablet bottle with a black TPD label for BPC-157 Oral, a glass of water and a small dish of white tablets beside it
One tablet with some water, as described in the entry. Symbolic image.

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

What the research shows

BPC-157 is broadly described preclinically, especially for gastrointestinal protection and wound healing (overview: Seiwerth/Sikiric, 2021). On oral bioavailability in humans the data is thin. Honestly: plausible for local gut effects, for systemic action the injection is the better-evidenced route.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Where the knowledge on BPC-157 comes from5

Share of the 36 studies in a systematic review (literature up to June 2024)

Systematic review5 35 preclinical, 1 clinical study
Animal and cell studies 97.2%
Human studies 2.8%

The only human study in the review was a retrospective analysis of knee injections: 7 of 12 people reported less pain for more than 6 months. No comparison group.

Participants by route6

Share of the 30 people from all three published human studies (systematic review up to June 2026)

Systematic review6 16 into the knee, 12 into the bladder, 2 into a vein, 0 by mouth
Into the knee 53.3%
Into the bladder 40.0%
Into a vein 6.7%
Tablet or capsule 0.0%

All three studies without a control group, the review rates the certainty of evidence as very low. The completed gummy study has not published results so far.

Row of sealed test tubes, each holding a small glass stomach
Almost all data from animal and cell studies. Symbolic image.

Research status

Where the research stands

Registered trials on the compound BPC-157. There is a phase 1 tablet trial (NCT02637284, started 2015), listed with unknown status and no results. The phase 1 trial after shoulder surgery (under the skin) has been announced but is not recruiting yet. As of 26 Oct 2026. 7

  1. Preclinical Animal and cell studies, including dosing in drinking water
  2. Phase 1 1 trial, 0 completed
  3. Phase 2 no registered trial
  4. Phase 3 no registered trial
  5. Approval not yet
Not approved. ChEMBL lists BPC-157 with phase 1 as the highest phase, without approval and without a recorded mechanism.7
Show all 1 trial on a timelineHide timeline 1 completed 0 running 0 with results
Without phase

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 1 trial on safety and pharmacokinetics, not shown as bars.

Side effects

  • Generally well tolerated.
  • Solid human data are largely missing.

Tolerability

Side effects in the human studies

Out of 100 participants, how many had a treatment-related side effect. Three small studies without placebo, none with a tablet.

0 of 100 Participants
Event Participants
Treatment-related side effects6 0%

Zero does not mean safe here: 30 people without a comparison group are not enough to detect rare or late side effects. A second review found no clinical safety data and warns of risks from unregulated manufacturing.65

Storage

Store dry, cool and protected from light, out of reach of children. Keep the original container closed and mind the expiry date.

Three white tablet bottles on a bright shelf next to a folded light blue towel
Dry, cool and away from light, bottle closed. Symbolic image.

Related

Related compounds

Same compounds, blends with BPC-157 Oral (Tablet) or a different path: all in the TPD lexicon.

BPC-157 Oral (Tablet)
BPC-157 Main entry, BPC-157 as an injection BPC-157 Oral (Capsule) The same compound as a capsule BPC + TB Oral Blend Contains BPC-157 plus TB-500, as a tablet BPC + TB Blend Contains BPC-157 plus TB-500 for injection Klow Blend Contains BPC-157 plus TB-500, GHK-Cu and KPV TB-500 (Thymosin Beta-4) Different peptide focused on tissue repair KPV Oral Different peptide as a tablet focused on the gut

FAQ

Common questions about BPC-157 Oral (Tablet)

Short answers, each backed by the sources below.

Is the tablet different from the capsule?

Not in terms of the compound. Tablet and capsule both contain BPC-157, only the dosage form differs. There are no comparative data between the two forms and no published human study of either.6

Is BPC-157 absorbed by mouth at all?

According to a review by the developer group, BPC-157 is stable in human gastric juice. In rat studies it worked via the drinking water much like when injected. There are no blood measurements after oral dosing. After dosing into muscle 14 to 19 percent reached the blood in rats and 45 to 51 percent in dogs, the half-life was under 30 minutes.234

What do the animal studies show for the gut?

In rats with a fistula between colon and skin the colon and skin defects healed faster when BPC-157 was injected or added to the drinking water. In short bowel syndrome the animals given BPC-157 by mouth or by injection started gaining weight again right away. There are also findings on alcohol and painkiller damage to the stomach and oesophagus.32

Are there studies in humans?

Very few. A systematic review up to June 2026 found three studies with 30 people in total: dosing into the knee, into the bladder and a small safety study into a vein. All without a control group, none with a tablet. The registry also lists a phase 1 tablet study from 2015 and a gummy study completed in 2025, both without published results.67

Which trials are running right now?

As of 26 October 2026 no trial with BPC-157 is recruiting. A phase 1 trial with 30 planned participants after shoulder surgery has been announced, where BPC-157 is injected under the skin, with the start planned for January 2027. No tablet trial is currently running.7

Which side effects are known?

No treatment-related side effects occurred in the three small human studies, but the certainty is very low. One review found no clinical safety data and names risks from unregulated manufacturing and contamination. There are no data of its own on the tablet.65

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Bioavailability
The share of a substance that actually reaches the blood after dosing.
Connective tissue
Supporting tissue such as tendons, ligaments and joint capsules.
Fistula
An abnormal connection between two organs or between an organ and the skin, for example between gut and skin.
Gastric juice
Acidic fluid in the stomach that breaks down many proteins and peptides.
Half-life
The time until the amount in the blood has fallen by half.
Mucosa
The inner lining of stomach and gut that protects the tissue beneath.
Pentadecapeptide
A peptide of exactly 15 amino acids. BPC-157 is such a fragment of a protein from gastric juice.
Placebo
Dummy preparation without active substance. Comparing against it shows what is due to the substance itself.
Preclinical
Research before first use in humans, in cell cultures and animal models.
Systematic review
An analysis of all studies on one question following fixed rules. Shows how much research there is and how good it is.
Systemic
Acting throughout the body, spread via the blood. The opposite is local, only at the site of dosing.
WADA
World Anti-Doping Agency. Its prohibited list applies to competitive sport.

Evidence

Sources

Show all 9 sourcesHide sources 6 Studies2 Trial registry1 Database checked 26 Oct 2026

Studies

  1. Review of BPC-157 and wound healing

    Seiwerth et al., Frontiers in Pharmacology, 2021

    DOI 10.3389/fphar.2021.627533 PMID 34267654
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Review of BPC-157 in the gastrointestinal tract

    Sikiric et al., Current Pharmaceutical Design, 2011

    DOI 10.2174/138161211796196954 PMID 21548867
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. BPC-157 injected or in drinking water for colocutaneous fistulas (rats)

    Klicek et al., Journal of Pharmacological Sciences, 2008

    DOI 10.1254/jphs.fp0072161 PMID 18818478
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Absorption, distribution and breakdown of BPC-157 (rats, dogs)

    He et al., Frontiers in Pharmacology, 2022

    DOI 10.3389/fphar.2022.1026182 PMID 36588717
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Systematic review of BPC-157 in orthopaedic sports medicine

    Vasireddi et al., HSS Journal, 2025

    DOI 10.1177/15563316251355551 PMID 40756949
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. Systematic review of all human studies on BPC-157

    Poolton et al., Acta Orthopaedica Belgica, 2026

    DOI 10.52628/92.3.15837 PMID 42885452
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials on BPC-157 on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2
  2. Registry record of the gummy study

    ClinicalTrials.gov, NCT07752381 (abgeschlossen 2025, ohne Ergebnisse)

    NCT07752381
    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. BPC-157 in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL4297358)

    Checked 26 Oct 2026 via ChEMBL

In the shop

BPC-157 Oral (Tablet) in the catalog

Sizes, prices and shipping times are on the product page.

To the product